TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma

Stage IVA Oral Cavity Squamous Cell Carcinoma Clinical Trial

Official title:
Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

Status Completed

Clinical Trial Summary

Induction chemotherapy is regarded as an effective way to reduce or downgrade the locally advanced or aggressive cancers, and to improve the chance of eradication of the locoregional lesions by radical surgery and/or radiotherapy. However, there are still debates on the clinical value of induction chemotherapy for patients with advanced and resectable oral squamous cell carcinoma. The hypothesis of this study is that the induction chemotherapy of TPF (docetaxel, cisplatin, and 5-fluorouracil) protocol could benefit the patients with locally advanced oral squamous cell carcinoma. The endpoints of this study are the survival rate, local control, and safety.

Clinical Trial Description

The primary endpoint of this study is the survival rate (2, 3, 5 years) after induction chemotherapy followed by surgery and radiotherapy. The second endpoint of this study is locoregional control rates (1, 2 years), and the safety. ;

Study Design

Related Conditions & MeSH terms

Carcinoma
Carcinoma, Squamous Cell
Stage III Oral Cavity Squamous Cell Carcinoma
Stage IVA Oral Cavity Squamous Cell Carcinoma

Clinical Trial Details

NCT number	NCT01542931
Study type	Interventional
Source	Shanghai Jiao Tong University School of Medicine
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	January 2008
Completion date	December 31, 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01469429` - Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.	Phase 1/Phase 2
Completed	`NCT03342911` - Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery	Phase 2
Terminated	`NCT02388932` - Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer	N/A
Completed	`NCT02827838` - Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer	Phase 2
Terminated	`NCT02334319` - Ganetespib Window of Opportunity Study in Head and Neck Cancers	Phase 1
Active, not recruiting	`NCT01267240` - Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer	Phase 2
Completed	`NCT02035527` - Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	Phase 1